About
Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company was founded in June 2004 and is headquartered in Morrisville, NC.
Current Value
$14.021 Year Return
Current Value
$14.021 Year Return
Key Details
Market Cap
$1.24B
P/E Ratio
-8.76
1Y Stock Return
-5.41%
1Y Revenue Growth
-19.97%
Dividend Yield
0.00%
Price to Book
15.9
Strategies that include LQDA
Double maintains 2 strategies that include LQDA - Liquidia Corp.
High risk
$1,000
0.51%
Growth at a Fair Price
These stocks above $1B in Market Cap are modestly valued (PE below 15) but are in the top 20% of stocks for revenue growth over the past 5 years. We weight them by market cap.
Top Sector
Health Care
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
195
Medium risk
$13,000
0.01%
Health Care Sector
This Strategy focuses on healthcare companies, including pharmaceuticals, biotechnology, healthcare providers, and medical equipment firms. Offering exposure to a sector driven by demographic trends and ongoing medical advancements, it's a strategic choice for investors considering healthcare's long-term growth potential.
Top Sector
Health Care
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
348
Stock's related to LQDA
The stocks that are correlated to LQDA - Liquidia Corp. are COHR, LLY, OGI, APH, MKSI
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| COHRCoherent Corp. | 36.05% | $10.47B | +13.63% | 0.00% |
| 30.99% | $775.66B | +5.44% | 0.68% | |
| 30.48% | $130.00M | -55.02% | 0.00% | |
| 29.75% | $82.28B | +17.71% | 0.97% | |
| 29.51% | $5.48B | -38.72% | 1.27% | |
| 29.33% | $7.71B | +2.32% | 0.00% | |
| 28.90% | $7.61B | +6.33% | 0.00% | |
| 28.83% | $3.44B | +35.82% | 0.00% | |
| 28.73% | $126.83B | -8.85% | 0.00% | |
| 28.47% | $28.27B | -9.11% | 1.04% | |
| 28.41% | $111.20B | -11.56% | 1.49% | |
| 28.17% | $883.62B | +19.99% | 1.55% | |
| 28.02% | $83.19B | +22.14% | 3.34% | |
| 27.82% | $2.98B | +46.22% | 0.00% | |
| 27.75% | $5.21B | +1.76% | 0.00% | |
| 27.73% | $19.60B | -18.50% | 3.78% | |
 KLACKLA Corp. | 27.55% | $91.19B | -1.63% | 0.99% |
| 27.51% | $7.19B | -12.42% | 0.00% | |
| 27.37% | $113.98B | -13.70% | 0.00% | |
| 27.32% | $3.64B | -2.74% | 0.48% | |
ETF's related to LQDA
The ETFs that are correlated to LQDA - Liquidia Corp. are FTQI, PTH, QFLR, FBCG, IPO
Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| 34.17% | $574.50M | 0.75% | |
| 33.98% | $107.91M | 0.6% | |
| 33.71% | $258.37M | 0.89% | |
| 33.52% | $3.54B | 0.59% | |
| 33.52% | $130.61M | 0.6% | |
| 33.48% | $736.68M | 0.59% | |
| 33.48% | $168.60M | 0.45% | |
| 33.34% | $462.60M | 0.16% | |
| 33.26% | $5.39B | 0.13% | |
| 33.00% | $5.13B | 0.47% | |
| 32.91% | $680.81M | 0.57% | |
| 32.75% | $2.97B | 0.46% | |
| 32.71% | $13.93B | 0.15% | |
| 32.66% | $8.39B | 0.61% | |
| 32.56% | $280.74M | 0.59% | |
| 32.53% | $2.36B | 0.68% | |
| 32.53% | $698.01M | 0.95% | |
| 32.44% | $2.87B | 0.68% | |
| 32.40% | $48.67M | 0.76% | |
| 32.26% | $22.77B | 0.35% | |
News
Yahoo
MORRISVILLE, N.C., April 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the company will provide an overview of the company’s business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, beginning at 8:45 a.m. ET. Access to a webcast of the presentation will be available on the “Investors” page of
Yahoo
MORRISVILLE, N.C., April 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the company will provide an overview of the company’s business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, beginning at 8:45 a.m. ET. Access to a webcast of the presentation will be available on the “Investors” page of Li
Yahoo
FDA sets PDUFA goal date of May 24, 2025MORRISVILLE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with in
Yahoo
- Data from the ASCENT study of LIQ861 (YUTREPIA™) in PH-ILD patients highlights safety, tolerability, exploratory changes in six-minute walk distance, cardiac effort and quality of life - Case study highlights the long-term safety and tolerability of LIQ861 (YUTREPIA) in a PAH patient transitioning from parenteral treprostinil in INSPIRE study MORRISVILLE, N.C., March 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies fo
Yahoo
As the United States market experiences a rally with major indices like the S&P 500 and Nasdaq posting gains, investor sentiment is buoyed by reports of potential tariff reductions. In this environment, growth companies with significant insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the company's operations and prospects.
Yahoo
Liquidia ( NASDAQ:LQDA ) Full Year 2024 Results Key Financial Results Revenue: US$14.0m (down 20% from FY 2023). Net...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
0% Expense Ratios with TLH
We offer over 50 indexes with zero expense ratios.
Registration will take about 10 seconds